1.325USD-2.57%Mkt Cap: 49.51M USDP/E: —Last update: 2026-06-01
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long prote…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap49.51M USD
Enterprise Value-49.78M USD
Revenue (TTM)22.33M USD
Gross Profit-72.10M USD
Net Income (TTM)-87.87M USD
Revenue/Share0.5970 USD
Last Price1.325 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees119
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.93
PEG—
EV/EBITDA0.57
EV/Revenue-2.23
P/S2.29
P/B0.37
EPS (TTM)-2.29
EPS (Forward)-1.47
52W Range
1.2403% of range3.950
52W High3.950 USD
52W Low1.240 USD
Profitability
Gross Margin0.00%
Oper. Margin-1970.11%
EBITDA Margin0.00%
Profit Margin-348.54%
ROE-55.40%
ROA-39.74%
Growth
Revenue Growth-69.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.89M USD
CapEx (TTM)574.00K USD
FCF Margin-252.02%
FCF Yield-113.68%
Net Debt-100.98M USD
Net Debt/EBITDA1.15
Balance Sheet
Debt/Equity0.26
Current Ratio6.42
Quick Ratio6.23
Book Value/Sh3.660 USD
Cash/Share3.723 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)8.000 USD
Target Range7.000 USD – 9.000 USD
# Analysts2
Ownership
Shares Out.37.65M
Float27.35M
Insiders19.25%
Institutions19.32%
Short Interest
Short Ratio10.1d
Short % Float5.92%
Short % Out.4.80%
Shares Short1.81M
Short (prev mo.)1.87M
Technical
SMA 501.389 (-4.6%)
SMA 2001.786 (-25.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)176.46K
Avg Vol (10d)211.80K
Technical Indicators
RSI (14)48.7
MACD-0.0171
MACD Signal-0.0247
MACD Hist.+0.0076
BB Upper1.459 USD
BB Middle1.357 USD
BB Lower1.256 USD
BB Width14.97%
ATR (14)0.0690 USD
Vol Ratio (20d)0.86x